Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 08, 2023--IMV Inc. (the "Company" or "IMV") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exerci
Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the first quarter ended March 31, 2023.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 01, 2023--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act
The following issues have been halted by IIROC:
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 31, 2023--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company’s
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 27, 2023--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately.
IMV Inc. (NASDAQ:IMV) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good day and thank you for standing by. Welcome to IMV’s Fourth Quarter and Fiscal Year 2022 Results Webcast. Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Mr. Andrew Hall, Chief Executive […]
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 16, 2023--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C ("Stonegate") to explore strategic alternatives following a review of its business.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 09, 2023--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.
IMV Inc (NASDAQ: IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Related: IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity 8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy; Of